APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Nintedanib Generics

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Nintedanib Generics Industry Growth and Trends Forecast to 2032

Report ID 174017130127 December 202599 pages

Choose your research edition.

Industry ResearchNintedanib Generics Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Nintedanib Generics Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Nintedanib Generics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nintedanib Generics Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Nintedanib Generics Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Nintedanib Generics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Nintedanib Generics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Nintedanib Generics is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Nintedanib Generics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Nintedanib Generics include CSPC Pharmaceutical Group, PuraCap, Qilu Pharmaceutical, Kelun Pharmaceutical, Jiangsu Wangao Pharmaceutical, Glenmark, Eskayef Pharmaceuticals, Cipla and Beacon Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Nintedanib Generics market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Nintedanib Generics market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Nintedanib Generics market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Nintedanib Generics.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Nintedanib Generics market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Nintedanib Generics Market by Company

CSPC Pharmaceutical Group

PuraCap

Qilu Pharmaceutical

Kelun Pharmaceutical

Jiangsu Wangao Pharmaceutical

Glenmark

Eskayef Pharmaceuticals

Cipla

Beacon Pharma

Nintedanib Generics Segment by Type

100mg per Unit

150mg per Unit

Nintedanib Generics Segment by Application

Non-small Cell Lung Cancer

Idiopathic Pulmonary Fibrosis

Other

Nintedanib Generics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nintedanib Generics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nintedanib Generics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nintedanib Generics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Nintedanib Generics manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Nintedanib Generics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of 100mg per Unit Table 2. Major Company of 150mg per Unit Table 3. Global Nintedanib Generics Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Nintedanib Generics Sales by Type (2021-2026) & (K Units) Table 5. Global Nintedanib Generics Sales Market Share in Volume by Type (2021-2026) Table 6. Global Nintedanib Generics Sales by Type (2021-2026) & (US$ Million) Table 7. Global Nintedanib Generics Sales Market Share in Value by Type (2021-2026) Table 8. Global Nintedanib Generics Price by Type (2021-2026) & (US$/Unit) Table 9. Global Nintedanib Generics Sales by Type (2027-2032) & (K Units) Table 10. Global Nintedanib Generics Sales Market Share in Volume by Type (2027-2032) Table 11. Global Nintedanib Generics Sales by Type (2027-2032) & (US$ Million) Table 12. Global Nintedanib Generics Sales Market Share in Value by Type (2027-2032) Table 13. Global Nintedanib Generics Price by Type (2027-2032) & (US$/Unit) Table 14. North America Nintedanib Generics Sales by Type (2021-2026) & (K Units) Table 15. North America Nintedanib Generics Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Nintedanib Generics Sales by Type (2021-2026) & (K Units) Table 17. Europe Nintedanib Generics Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Nintedanib Generics Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Nintedanib Generics Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Nintedanib Generics Sales by Type (2021-2026) & (K Units) Table 21. Latin America Nintedanib Generics Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Nintedanib Generics Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Nintedanib Generics Sales by Type (2021-2026) & (US$ Million) Table 24. Nintedanib Generics Industry Trends Table 25. Nintedanib Generics Industry Drivers Table 26. Nintedanib Generics Industry Opportunities and Challenges Table 27. Nintedanib Generics Industry Restraints Table 28. Global Nintedanib Generics Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Nintedanib Generics Revenue Market Share by Company (2021-2026) Table 30. Global Nintedanib Generics Sales by Company (2021-2026) & (K Units) Table 31. Global Nintedanib Generics Sales Share by Company (2021-2026) Table 32. Global Nintedanib Generics Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Nintedanib Generics Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Nintedanib Generics Major Company Production Sites and Headquarters Table 35. Global Nintedanib Generics Company, Product Type & Application Table 36. Global Nintedanib Generics Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Nintedanib Generics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Nintedanib Generics Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Nintedanib Generics Sales by Region (2021-2026) & (K Units) Table 41. Global Nintedanib Generics Sales Market Share in Volume by Region (2021-2026) Table 42. Global Nintedanib Generics Sales by Region (2021-2026) & (US$ Million) Table 43. Global Nintedanib Generics Sales Market Share in Value by Region (2021-2026) Table 44. Global Nintedanib Generics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Nintedanib Generics Sales by Region (2027-2032) & (K Units) Table 46. Global Nintedanib Generics Sales Market Share in Volume by Region (2027-2032) Table 47. Global Nintedanib Generics Sales by Region (2027-2032) & (US$ Million) Table 48. Global Nintedanib Generics Sales Market Share in Value by Region (2027-2032) Table 49. Global Nintedanib Generics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Nintedanib Generics Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Nintedanib Generics Sales by Application (2021-2026) & (K Units) Table 52. Global Nintedanib Generics Sales Market Share in Volume by Application (2021-2026) Table 53. Global Nintedanib Generics Sales by Application (2021-2026) & (US$ Million) Table 54. Global Nintedanib Generics Sales Market Share in Value by Application (2021-2026) Table 55. Global Nintedanib Generics Price by Application (2021-2026) & (US$/Unit) Table 56. Global Nintedanib Generics Sales by Application (2027-2032) & (K Units) Table 57. Global Nintedanib Generics Sales Market Share in Volume by Application (2027-2032) Table 58. Global Nintedanib Generics Sales by Application (2027-2032) & (US$ Million) Table 59. Global Nintedanib Generics Sales Market Share in Value by Application (2027-2032) Table 60. Global Nintedanib Generics Price by Application (2027-2032) & (US$/Unit) Table 61. North America Nintedanib Generics Sales by Application (2021-2026) & (K Units) Table 62. North America Nintedanib Generics Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Nintedanib Generics Sales by Application (2021-2026) & (K Units) Table 64. Europe Nintedanib Generics Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Nintedanib Generics Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Nintedanib Generics Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Nintedanib Generics Sales by Application (2021-2026) & (K Units) Table 68. Latin America Nintedanib Generics Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Nintedanib Generics Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Nintedanib Generics Sales by Application (2021-2026) & (US$ Million) Table 71. CSPC Pharmaceutical Group Company Information Table 72. CSPC Pharmaceutical Group Business Overview Table 73. CSPC Pharmaceutical Group Nintedanib Generics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. CSPC Pharmaceutical Group Nintedanib Generics Product Portfolio Table 75. CSPC Pharmaceutical Group Recent Development Table 76. PuraCap Company Information Table 77. PuraCap Business Overview Table 78. PuraCap Nintedanib Generics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. PuraCap Nintedanib Generics Product Portfolio Table 80. PuraCap Recent Development Table 81. Qilu Pharmaceutical Company Information Table 82. Qilu Pharmaceutical Business Overview Table 83. Qilu Pharmaceutical Nintedanib Generics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Qilu Pharmaceutical Nintedanib Generics Product Portfolio Table 85. Qilu Pharmaceutical Recent Development Table 86. Kelun Pharmaceutical Company Information Table 87. Kelun Pharmaceutical Business Overview Table 88. Kelun Pharmaceutical Nintedanib Generics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Kelun Pharmaceutical Nintedanib Generics Product Portfolio Table 90. Kelun Pharmaceutical Recent Development Table 91. Jiangsu Wangao Pharmaceutical Company Information Table 92. Jiangsu Wangao Pharmaceutical Business Overview Table 93. Jiangsu Wangao Pharmaceutical Nintedanib Generics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Jiangsu Wangao Pharmaceutical Nintedanib Generics Product Portfolio Table 95. Jiangsu Wangao Pharmaceutical Recent Development Table 96. Glenmark Company Information Table 97. Glenmark Business Overview Table 98. Glenmark Nintedanib Generics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Glenmark Nintedanib Generics Product Portfolio Table 100. Glenmark Recent Development Table 101. Eskayef Pharmaceuticals Company Information Table 102. Eskayef Pharmaceuticals Business Overview Table 103. Eskayef Pharmaceuticals Nintedanib Generics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Eskayef Pharmaceuticals Nintedanib Generics Product Portfolio Table 105. Eskayef Pharmaceuticals Recent Development Table 106. Cipla Company Information Table 107. Cipla Business Overview Table 108. Cipla Nintedanib Generics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Cipla Nintedanib Generics Product Portfolio Table 110. Cipla Recent Development Table 111. Beacon Pharma Company Information Table 112. Beacon Pharma Business Overview Table 113. Beacon Pharma Nintedanib Generics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Beacon Pharma Nintedanib Generics Product Portfolio Table 115. Beacon Pharma Recent Development Table 116. North America Nintedanib Generics Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 117. North America Nintedanib Generics Sales by Country (2021-2026) & (K Units) Table 118. North America Nintedanib Generics Sales Market Share by Country (2021-2026) Table 119. North America Nintedanib Generics Sales Forecast by Country (2027-2032) & (K Units) Table 120. North America Nintedanib Generics Sales Market Share Forecast by Country (2027-2032) Table 121. North America Nintedanib Generics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 122. North America Nintedanib Generics Market Size by Country (2021-2026) & (US$ Million) Table 123. North America Nintedanib Generics Market Share by Country (2021-2026) Table 124. North America Nintedanib Generics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 125. North America Nintedanib Generics Market Share Forecast by Country (2027-2032) Table 126. Europe Nintedanib Generics Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 127. Europe Nintedanib Generics Sales by Country (2021-2026) & (K Units) Table 128. Europe Nintedanib Generics Sales Market Share by Country (2021-2026) Table 129. Europe Nintedanib Generics Sales Forecast by Country (2027-2032) & (K Units) Table 130. Europe Nintedanib Generics Sales Market Share Forecast by Country (2027-2032) Table 131. Europe Nintedanib Generics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 132. Europe Nintedanib Generics Market Size by Country (2021-2026) & (US$ Million) Table 133. Europe Nintedanib Generics Market Share by Country (2021-2026) Table 134. Europe Nintedanib Generics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 135. Europe Nintedanib Generics Market Share Forecast by Country (2027-2032) Table 136. Asia-Pacific Nintedanib Generics Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 137. Asia-Pacific Nintedanib Generics Sales by Country (2021-2026) & (K Units) Table 138. Asia-Pacific Nintedanib Generics Sales Market Share by Country (2021-2026) Table 139. Asia-Pacific Nintedanib Generics Sales Forecast by Country (2027-2032) & (K Units) Table 140. Asia-Pacific Nintedanib Generics Sales Market Share Forecast by Country (2027-2032) Table 141. Asia-Pacific Nintedanib Generics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 142. Asia-Pacific Nintedanib Generics Market Size by Country (2021-2026) & (US$ Million) Table 143. Asia-Pacific Nintedanib Generics Market Share by Country (2021-2026) Table 144. Asia-Pacific Nintedanib Generics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 145. Asia-Pacific Nintedanib Generics Market Share Forecast by Country (2027-2032) Table 146. Latin America Nintedanib Generics Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 147. Latin America Nintedanib Generics Sales by Country (2021-2026) & (K Units) Table 148. Latin America Nintedanib Generics Sales Market Share by Country (2021-2026) Table 149. Latin America Nintedanib Generics Sales Forecast by Country (2027-2032) & (K Units) Table 150. Latin America Nintedanib Generics Sales Market Share Forecast by Country (2027-2032) Table 151. Latin America Nintedanib Generics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 152. Latin America Nintedanib Generics Market Size by Country (2021-2026) & (US$ Million) Table 153. Latin America Nintedanib Generics Market Share by Country (2021-2026) Table 154. Latin America Nintedanib Generics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 155. Latin America Nintedanib Generics Market Share Forecast by Country (2027-2032) Table 156. Middle East and Africa Nintedanib Generics Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 157. Middle East and Africa Nintedanib Generics Sales by Country (2021-2026) & (K Units) Table 158. Middle East and Africa Nintedanib Generics Sales Market Share by Country (2021-2026) Table 159. Middle East and Africa Nintedanib Generics Sales Forecast by Country (2027-2032) & (K Units) Table 160. Middle East and Africa Nintedanib Generics Sales Market Share Forecast by Country (2027-2032) Table 161. Middle East and Africa Nintedanib Generics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 162. Middle East and Africa Nintedanib Generics Market Size by Country (2021-2026) & (US$ Million) Table 163. Middle East and Africa Nintedanib Generics Market Share by Country (2021-2026) Table 164. Middle East and Africa Nintedanib Generics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 165. Middle East and Africa Nintedanib Generics Market Share Forecast by Country (2027-2032) Table 166. Key Raw Materials Table 167. Raw Materials Key Suppliers Table 168. Nintedanib Generics Distributors List Table 169. Nintedanib Generics Customers List Table 170. Research Programs/Design for This Report Table 171. Authors List of This Report Table 172. Secondary Sources Table 173. Primary Sources List of Figures Figure 1. Nintedanib Generics Image Figure 2. Global Nintedanib Generics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nintedanib Generics Market Size (2021-2032) & (US$ Million) Figure 4. Global Nintedanib Generics Sales (2021-2032) & (K Units) Figure 5. 100mg per Unit Image Figure 6. Global 100mg per Unit Sales YoY Growth (2021-2032) & (K Units) Figure 7. 150mg per Unit Image Figure 8. Global 150mg per Unit Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Nintedanib Generics Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Nintedanib Generics Market Share by Type 2025 VS 2032 Figure 11. North America Nintedanib Generics Sales Market Share in Volume by Type in 2025 Figure 12. North America Nintedanib Generics Sales Market Share in Value by Type in 2025 Figure 13. Europe Nintedanib Generics Sales Market Share in Volume by Type in 2025 Figure 14. Europe Nintedanib Generics Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Nintedanib Generics Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Nintedanib Generics Sales Market Share in Value by Type in 2025 Figure 17. Latin America Nintedanib Generics Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Nintedanib Generics Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Nintedanib Generics Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Nintedanib Generics Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Nintedanib Generics Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Non-small Cell Lung Cancer Image Figure 24. Global Non-small Cell Lung Cancer Sales YoY Growth (2021-2032) & (K Units) Figure 25. Idiopathic Pulmonary Fibrosis Image Figure 26. Global Idiopathic Pulmonary Fibrosis Sales YoY Growth (2021-2032) & (K Units) Figure 27. Other Image Figure 28. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 29. Global Nintedanib Generics Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Nintedanib Generics Market Share by Application 2025 VS 2032 Figure 31. North America Nintedanib Generics Sales Market Share in Volume by Application in 2025 Figure 32. North America Nintedanib Generics Sales Market Share in Value by Application in 2025 Figure 33. Europe Nintedanib Generics Sales Market Share in Volume by Application in 2025 Figure 34. Europe Nintedanib Generics Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Nintedanib Generics Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Nintedanib Generics Sales Market Share in Value by Application in 2025 Figure 37. Latin America Nintedanib Generics Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Nintedanib Generics Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Nintedanib Generics Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Nintedanib Generics Sales Market Share in Value by Application in 2025 Figure 41. North America Nintedanib Generics Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 42. North America Nintedanib Generics Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Nintedanib Generics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Nintedanib Generics Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Nintedanib Generics Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. Europe Nintedanib Generics Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Nintedanib Generics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Nintedanib Generics Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Nintedanib Generics Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Asia-Pacific Nintedanib Generics Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Nintedanib Generics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Nintedanib Generics Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Nintedanib Generics Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Latin America Nintedanib Generics Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Nintedanib Generics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Nintedanib Generics Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Nintedanib Generics Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Middle East and Africa Nintedanib Generics Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Nintedanib Generics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Nintedanib Generics Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Nintedanib Generics Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Nintedanib Generics Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • 100mg per Unit
  • 150mg per Unit
Applications
  • Non-small Cell Lung Cancer
  • Idiopathic Pulmonary Fibrosis
  • Other
Companies covered
  • CSPC Pharmaceutical Group
  • PuraCap
  • Qilu Pharmaceutical
  • Kelun Pharmaceutical
  • Jiangsu Wangao Pharmaceutical
  • Glenmark
  • Eskayef Pharmaceuticals
  • Cipla
  • Beacon Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Nintedanib Generics Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Nintedanib Generics Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Nintedanib Generics Market by Type
  6. 1.3.1 100mg per Unit
  7. 1.3.2 150mg per Unit
  8. 1.4 Global Nintedanib Generics Market Size by Type
  9. 1.4.1 Global Nintedanib Generics Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Nintedanib Generics Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Nintedanib Generics Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Nintedanib Generics Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Nintedanib Generics Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Nintedanib Generics Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Nintedanib Generics Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Nintedanib Generics Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Nintedanib Generics Industry Trends
  2. 2.2 Nintedanib Generics Industry Drivers
  3. 2.3 Nintedanib Generics Industry Opportunities and Challenges
  4. 2.4 Nintedanib Generics Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Nintedanib Generics Revenue (2021-2026)
  2. 3.2 Global Top Players by Nintedanib Generics Sales (2021-2026)
  3. 3.3 Global Top Players by Nintedanib Generics Price (2021-2026)
  4. 3.4 Global Nintedanib Generics Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Nintedanib Generics Major Company Production Sites & Headquarters
  6. 3.6 Global Nintedanib Generics Company, Product Type & Application
  7. 3.7 Global Nintedanib Generics Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Nintedanib Generics Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Nintedanib Generics Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Nintedanib Generics Tier 1, Tier 2, and Tier 3
4 Nintedanib Generics Regional Status and Outlook
  1. 4.1 Global Nintedanib Generics Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Nintedanib Generics Historic Market Size by Region
  3. 4.2.1 Global Nintedanib Generics Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Nintedanib Generics Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Nintedanib Generics Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Nintedanib Generics Forecasted Market Size by Region
  7. 4.3.1 Global Nintedanib Generics Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Nintedanib Generics Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Nintedanib Generics Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Nintedanib Generics by Application
  1. 5.1 Nintedanib Generics Market by Application
  2. 5.1.1 Non-small Cell Lung Cancer
  3. 5.1.2 Idiopathic Pulmonary Fibrosis
  4. 5.1.3 Other
  5. 5.2 Global Nintedanib Generics Market Size by Application
  6. 5.2.1 Global Nintedanib Generics Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Nintedanib Generics Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Nintedanib Generics Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Nintedanib Generics Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Nintedanib Generics Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Nintedanib Generics Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Nintedanib Generics Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Nintedanib Generics Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 CSPC Pharmaceutical Group
  2. 6.1.1 CSPC Pharmaceutical Group Company Information
  3. 6.1.2 CSPC Pharmaceutical Group Business Overview
  4. 6.1.3 CSPC Pharmaceutical Group Nintedanib Generics Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 CSPC Pharmaceutical Group Nintedanib Generics Product Portfolio
  6. 6.1.5 CSPC Pharmaceutical Group Recent Developments
  7. 6.2 PuraCap
  8. 6.2.1 PuraCap Company Information
  9. 6.2.2 PuraCap Business Overview
  10. 6.2.3 PuraCap Nintedanib Generics Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 PuraCap Nintedanib Generics Product Portfolio
  12. 6.2.5 PuraCap Recent Developments
  13. 6.3 Qilu Pharmaceutical
  14. 6.3.1 Qilu Pharmaceutical Company Information
  15. 6.3.2 Qilu Pharmaceutical Business Overview
  16. 6.3.3 Qilu Pharmaceutical Nintedanib Generics Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Qilu Pharmaceutical Nintedanib Generics Product Portfolio
  18. 6.3.5 Qilu Pharmaceutical Recent Developments
  19. 6.4 Kelun Pharmaceutical
  20. 6.4.1 Kelun Pharmaceutical Company Information
  21. 6.4.2 Kelun Pharmaceutical Business Overview
  22. 6.4.3 Kelun Pharmaceutical Nintedanib Generics Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Kelun Pharmaceutical Nintedanib Generics Product Portfolio
  24. 6.4.5 Kelun Pharmaceutical Recent Developments
  25. 6.5 Jiangsu Wangao Pharmaceutical
  26. 6.5.1 Jiangsu Wangao Pharmaceutical Company Information
  27. 6.5.2 Jiangsu Wangao Pharmaceutical Business Overview
  28. 6.5.3 Jiangsu Wangao Pharmaceutical Nintedanib Generics Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Jiangsu Wangao Pharmaceutical Nintedanib Generics Product Portfolio
  30. 6.5.5 Jiangsu Wangao Pharmaceutical Recent Developments
  31. 6.6 Glenmark
  32. 6.6.1 Glenmark Company Information
  33. 6.6.2 Glenmark Business Overview
  34. 6.6.3 Glenmark Nintedanib Generics Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Glenmark Nintedanib Generics Product Portfolio
  36. 6.6.5 Glenmark Recent Developments
  37. 6.7 Eskayef Pharmaceuticals
  38. 6.7.1 Eskayef Pharmaceuticals Company Information
  39. 6.7.2 Eskayef Pharmaceuticals Business Overview
  40. 6.7.3 Eskayef Pharmaceuticals Nintedanib Generics Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Eskayef Pharmaceuticals Nintedanib Generics Product Portfolio
  42. 6.7.5 Eskayef Pharmaceuticals Recent Developments
  43. 6.8 Cipla
  44. 6.8.1 Cipla Company Information
  45. 6.8.2 Cipla Business Overview
  46. 6.8.3 Cipla Nintedanib Generics Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Cipla Nintedanib Generics Product Portfolio
  48. 6.8.5 Cipla Recent Developments
  49. 6.9 Beacon Pharma
  50. 6.9.1 Beacon Pharma Company Information
  51. 6.9.2 Beacon Pharma Business Overview
  52. 6.9.3 Beacon Pharma Nintedanib Generics Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Beacon Pharma Nintedanib Generics Product Portfolio
  54. 6.9.5 Beacon Pharma Recent Developments
7 North America by Country
  1. 7.1 North America Nintedanib Generics Sales by Country
  2. 7.1.1 North America Nintedanib Generics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Nintedanib Generics Sales by Country (2021-2026)
  4. 7.1.3 North America Nintedanib Generics Sales Forecast by Country (2027-2032)
  5. 7.2 North America Nintedanib Generics Market Size by Country
  6. 7.2.1 North America Nintedanib Generics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Nintedanib Generics Market Size by Country (2021-2026)
  8. 7.2.3 North America Nintedanib Generics Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Nintedanib Generics Sales by Country
  2. 8.1.1 Europe Nintedanib Generics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Nintedanib Generics Sales by Country (2021-2026)
  4. 8.1.3 Europe Nintedanib Generics Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Nintedanib Generics Market Size by Country
  6. 8.2.1 Europe Nintedanib Generics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Nintedanib Generics Market Size by Country (2021-2026)
  8. 8.2.3 Europe Nintedanib Generics Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Nintedanib Generics Sales by Country
  2. 9.1.1 Asia-Pacific Nintedanib Generics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Nintedanib Generics Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Nintedanib Generics Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Nintedanib Generics Market Size by Country
  6. 9.2.1 Asia-Pacific Nintedanib Generics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Nintedanib Generics Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Nintedanib Generics Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Nintedanib Generics Sales by Country
  2. 10.1.1 South America Nintedanib Generics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Nintedanib Generics Sales by Country (2021-2026)
  4. 10.1.3 South America Nintedanib Generics Sales Forecast by Country (2027-2032)
  5. 10.2 South America Nintedanib Generics Market Size by Country
  6. 10.2.1 South America Nintedanib Generics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Nintedanib Generics Market Size by Country (2021-2026)
  8. 10.2.3 South America Nintedanib Generics Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Nintedanib Generics Sales by Country
  2. 11.1.1 Middle East and Africa Nintedanib Generics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Nintedanib Generics Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Nintedanib Generics Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Nintedanib Generics Market Size by Country
  6. 11.2.1 Middle East and Africa Nintedanib Generics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Nintedanib Generics Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Nintedanib Generics Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Nintedanib Generics Value Chain Analysis
  2. 12.1.1 Nintedanib Generics Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Nintedanib Generics Production Mode & Process
  7. 12.2 Nintedanib Generics Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Nintedanib Generics Distributors
  10. 12.2.3 Nintedanib Generics Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst